BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17309338)

  • 1. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Expert Opin Pharmacother; 2007 Mar; 8(4):437-44. PubMed ID: 17309338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L; Delforge M; Dierickx D
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
    Sadler JE
    Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic thrombocytopenic purpura: from diagnosis to therapy.
    Mariotte E; Veyradier A
    Curr Opin Crit Care; 2015 Dec; 21(6):593-601. PubMed ID: 26418759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
    Bentley MJ; Wilson AR; Rodgers GM
    Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
    Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
    Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
    Duraković N; Radonić R; Gasparović V
    Coll Antropol; 2010 Sep; 34(3):1087-91. PubMed ID: 20977108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
    Froissart A; Veyradier A; Hié M; Benhamou Y; Coppo P;
    Eur J Intern Med; 2015 Nov; 26(9):659-65. PubMed ID: 26293834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
    Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G
    Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of thrombotic thrombocytopenic purpura.
    Kremer Hovinga JA; Meyer SC
    Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Yomtovian R; Niklinski W; Silver B; Sarode R; Tsai HM
    Br J Haematol; 2004 Mar; 124(6):787-95. PubMed ID: 15009067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P; Veyradier A
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic thrombocytopenic purpura in children.
    Loirat C; Coppo P; Veyradier A
    Curr Opin Pediatr; 2013 Apr; 25(2):216-24. PubMed ID: 23422353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cases of refractory thrombotic thrombocytopenic purpura associated with collagen vascular disease were significantly improved by rituximab treatment.
    Kameda T; Dobashi H; Kittaka K; Susaki K; Yamaoka G; Arai K; Tokuda M; Ishida T
    Clin Rheumatol; 2007 Dec; 26(12):2159-2162. PubMed ID: 17562094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic thrombocytopenic purpura: a moving target.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.